A Circulating MicroRNA Signature Capable of Assessing the Risk of Hepatocellular Carcinoma in Cirrhotic Patients

A Circulating MicroRNA Signature Capable of Assessing the Risk of Hepatocellular Carcinoma in Cirrhotic Patients

Abstract With the availability of potent antiviral therapies, complete suppression of hepatitis B virus (HBV) replication and total eradication of hepatitis C virus (HCV) can now be achieved. Despite these advances, hepatocellular carcinoma (HCC) still develops in a substantial proportion of cirrhot...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ya-Hui Huang, Kung-Hao Liang, Rong-Nan Chien, Tsung-Hui Hu, Kwang-Huei Lin, Chao-Wei Hsu, Chih-Lang Lin, Tai-Long Pan, Po-Yuan Ke, Chau-Ting Yeh
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/681de4d9890645de85abd9bbc8cfa40f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:681de4d9890645de85abd9bbc8cfa40f
record_format dspace
spelling oai:doaj.org-article:681de4d9890645de85abd9bbc8cfa40f2021-12-02T16:07:00ZA Circulating MicroRNA Signature Capable of Assessing the Risk of Hepatocellular Carcinoma in Cirrhotic Patients10.1038/s41598-017-00631-92045-2322https://doaj.org/article/681de4d9890645de85abd9bbc8cfa40f2017-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-00631-9https://doaj.org/toc/2045-2322Abstract With the availability of potent antiviral therapies, complete suppression of hepatitis B virus (HBV) replication and total eradication of hepatitis C virus (HCV) can now be achieved. Despite these advances, hepatocellular carcinoma (HCC) still develops in a substantial proportion of cirrhotic patients, suggesting that host factors remain critical. Dysregulation of miRNAs is noted in many cancers, and circulating miRNAs can be readily assayed. In this study, we aimed to develop a circulating miRNA signature to assess the risk of HCC in cirrhotic patients. We first discovered that HBV- and HCV-related cirrhotic patients had distinguishable circulating miRNA profiles. A cohort of 330 cirrhotic patients was then compared against a cohort of 42 early HCC patients with complete remission. A score comprising 5 miRNAs and a binary etiology variable was established that was capable of differentiating between these two groups (AUC = 72.5%, P < 0.001). The 330 cirrhotic patients were further stratified into high- and low-risk groups, and all patients were longitudinally followed for 752 (11–891) days. Of them, 19 patients developed HCC. The high-risk group had significantly higher cumulative HCC incidence (P = 0.038). In summary, a circulating miRNA-based score was developed that is capable of assessing HCC risks in cirrhotic patients.Ya-Hui HuangKung-Hao LiangRong-Nan ChienTsung-Hui HuKwang-Huei LinChao-Wei HsuChih-Lang LinTai-Long PanPo-Yuan KeChau-Ting YehNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-12 (2017)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Ya-Hui Huang
Kung-Hao Liang
Rong-Nan Chien
Tsung-Hui Hu
Kwang-Huei Lin
Chao-Wei Hsu
Chih-Lang Lin
Tai-Long Pan
Po-Yuan Ke
Chau-Ting Yeh
A Circulating MicroRNA Signature Capable of Assessing the Risk of Hepatocellular Carcinoma in Cirrhotic Patients
description Abstract With the availability of potent antiviral therapies, complete suppression of hepatitis B virus (HBV) replication and total eradication of hepatitis C virus (HCV) can now be achieved. Despite these advances, hepatocellular carcinoma (HCC) still develops in a substantial proportion of cirrhotic patients, suggesting that host factors remain critical. Dysregulation of miRNAs is noted in many cancers, and circulating miRNAs can be readily assayed. In this study, we aimed to develop a circulating miRNA signature to assess the risk of HCC in cirrhotic patients. We first discovered that HBV- and HCV-related cirrhotic patients had distinguishable circulating miRNA profiles. A cohort of 330 cirrhotic patients was then compared against a cohort of 42 early HCC patients with complete remission. A score comprising 5 miRNAs and a binary etiology variable was established that was capable of differentiating between these two groups (AUC = 72.5%, P < 0.001). The 330 cirrhotic patients were further stratified into high- and low-risk groups, and all patients were longitudinally followed for 752 (11–891) days. Of them, 19 patients developed HCC. The high-risk group had significantly higher cumulative HCC incidence (P = 0.038). In summary, a circulating miRNA-based score was developed that is capable of assessing HCC risks in cirrhotic patients.
format article
author Ya-Hui Huang
Kung-Hao Liang
Rong-Nan Chien
Tsung-Hui Hu
Kwang-Huei Lin
Chao-Wei Hsu
Chih-Lang Lin
Tai-Long Pan
Po-Yuan Ke
Chau-Ting Yeh
author_facet Ya-Hui Huang
Kung-Hao Liang
Rong-Nan Chien
Tsung-Hui Hu
Kwang-Huei Lin
Chao-Wei Hsu
Chih-Lang Lin
Tai-Long Pan
Po-Yuan Ke
Chau-Ting Yeh
author_sort Ya-Hui Huang
title A Circulating MicroRNA Signature Capable of Assessing the Risk of Hepatocellular Carcinoma in Cirrhotic Patients
title_short A Circulating MicroRNA Signature Capable of Assessing the Risk of Hepatocellular Carcinoma in Cirrhotic Patients
title_full A Circulating MicroRNA Signature Capable of Assessing the Risk of Hepatocellular Carcinoma in Cirrhotic Patients
title_fullStr A Circulating MicroRNA Signature Capable of Assessing the Risk of Hepatocellular Carcinoma in Cirrhotic Patients
title_full_unstemmed A Circulating MicroRNA Signature Capable of Assessing the Risk of Hepatocellular Carcinoma in Cirrhotic Patients
title_sort circulating microrna signature capable of assessing the risk of hepatocellular carcinoma in cirrhotic patients
publisher Nature Portfolio
publishDate 2017
url https://doaj.org/article/681de4d9890645de85abd9bbc8cfa40f
work_keys_str_mv AT yahuihuang acirculatingmicrornasignaturecapableofassessingtheriskofhepatocellularcarcinomaincirrhoticpatients
AT kunghaoliang acirculatingmicrornasignaturecapableofassessingtheriskofhepatocellularcarcinomaincirrhoticpatients
AT rongnanchien acirculatingmicrornasignaturecapableofassessingtheriskofhepatocellularcarcinomaincirrhoticpatients
AT tsunghuihu acirculatingmicrornasignaturecapableofassessingtheriskofhepatocellularcarcinomaincirrhoticpatients
AT kwanghueilin acirculatingmicrornasignaturecapableofassessingtheriskofhepatocellularcarcinomaincirrhoticpatients
AT chaoweihsu acirculatingmicrornasignaturecapableofassessingtheriskofhepatocellularcarcinomaincirrhoticpatients
AT chihlanglin acirculatingmicrornasignaturecapableofassessingtheriskofhepatocellularcarcinomaincirrhoticpatients
AT tailongpan acirculatingmicrornasignaturecapableofassessingtheriskofhepatocellularcarcinomaincirrhoticpatients
AT poyuanke acirculatingmicrornasignaturecapableofassessingtheriskofhepatocellularcarcinomaincirrhoticpatients
AT chautingyeh acirculatingmicrornasignaturecapableofassessingtheriskofhepatocellularcarcinomaincirrhoticpatients
AT yahuihuang circulatingmicrornasignaturecapableofassessingtheriskofhepatocellularcarcinomaincirrhoticpatients
AT kunghaoliang circulatingmicrornasignaturecapableofassessingtheriskofhepatocellularcarcinomaincirrhoticpatients
AT rongnanchien circulatingmicrornasignaturecapableofassessingtheriskofhepatocellularcarcinomaincirrhoticpatients
AT tsunghuihu circulatingmicrornasignaturecapableofassessingtheriskofhepatocellularcarcinomaincirrhoticpatients
AT kwanghueilin circulatingmicrornasignaturecapableofassessingtheriskofhepatocellularcarcinomaincirrhoticpatients
AT chaoweihsu circulatingmicrornasignaturecapableofassessingtheriskofhepatocellularcarcinomaincirrhoticpatients
AT chihlanglin circulatingmicrornasignaturecapableofassessingtheriskofhepatocellularcarcinomaincirrhoticpatients
AT tailongpan circulatingmicrornasignaturecapableofassessingtheriskofhepatocellularcarcinomaincirrhoticpatients
AT poyuanke circulatingmicrornasignaturecapableofassessingtheriskofhepatocellularcarcinomaincirrhoticpatients
AT chautingyeh circulatingmicrornasignaturecapableofassessingtheriskofhepatocellularcarcinomaincirrhoticpatients
_version_ 1718384779888427008

Ejemplares similares